History

2016

  • October
    • Entered a product licensing and marketing agreement with Eurofarma Laboratorios S.A. for farletuzumab in Latin America
    • September
      • Entered into a sponsored research and collaboration to develop human organoid systems from primary human tumors to study the effects of tumor immune suppression to improve patient selection of Morphotek first-in-class experimental therapies.
      • April
        • Announced publication of Phase 3 results from MORAb-003-004 trial in platinum-sensitive ovarian cancer patients.
      • March
        • Entered collaboration with Areva Med on lead-212 targeted alpha therapies.
      • February
        • Entered collaboration with Mayo Clinic to apply its folate receptor alpha diagnostic assays in a Phase 2 clinical trial in triple-negative breast cancer.
      • January
        • Selected Cryoport to manage cold chain logistics.

2015

  • December
    • Announced Phase 1 results from MORAb-022-001 trial in healthy subjects and patients with mild-to-moderate rheumatiod arthritis.
    • Entered collaboration with researchers at the University of Wisconsin-Madison to study the immunosuppressive effects of CA125 tumor antigen on immune-based therapies for ovarian cancer, including farletuzumab.
  • November
    • Initiated amatuximab ARTEMIS study in first-line, unresectable, malignant pleural mesothelioma patients.
    • Entered collaboration with researchers at the University of Gothenburg to develop a farletuzumab alpha-particle radioimmunotherapy for ovarian cancer.
    • Signed license agreement with Blaze Bioscience Inc. for the development of a novel oncology imaging technology using chlorotoxin peptide platform.
  • October
    • Presented preclinical findings at ESGO 19 on the potential immuno-suppressive effects of the CA125 tumor antigen on farletuzumab, an investigational anti-folate receptor alpha antibody.
  • March
    • Initiated farletuzumab clinical study in patients with first-relapsed, platinum-sensitive ovarian cancer with low levels of CA125 tumor antigen.
  • January
    • Recognized as Top-25 Life Sciences Company in the greater Philadelphia area.

2014

  • July
    • Entered into Research Option Agreement with Sorrento Therapeutics to develop antibody drug conjugates.
    • Entered into research collaboration with Stealth Biologics to develop deimmunized therapeutic proteins.
  • January
    • Granted orphan drug status by European commission for amatuximab for the treatment of malignant mesothelioma.

2013

  • October
    • Initiated a Phase 1 clinical study of ontuxizumab in pediatric cancers.
  • June
    • Initiated a Phase 1 clinical study of MORAb-066 in breast, pancreatic, colorectal and non-small cell lung cancer.
    • Received Governor's IMPACT award for entrepreneurship in Pennsylvania.
  • January
    • Pilot Plant awarded facility of the year for its design and innovative infrastructure.

2012

  • November
    • Granted orphan status by FDA for use of amatuximab in malignant pleural mesothelioma.
  • August
    • Initiated a global Phase 2 study of MORAb-004 in patients with metastatic soft tissue sarcoma.
    • Opened 60,000 sq. ft. state-of-the-art GMP pilot plant to support manufacturing of biopharmaceutical products.
  • May
    • Won Prestigious Innovation Award for assay development from The American Association of Pharmaceutical Scientists.
  • April
    • Initiated Phase 2 Clinical Study of MORAb-004 in chemorefractory metastatic colorectal cancer.
  • March
    • Formed a partnership with Biocare Medical to develop and commercialize an in vitro diagnostic immunohistochemical (IHC) kit to detect folate receptor alpha (FRA) expression in formalin-fixed paraffin-embedded (FFPE) malignant tissues. The kit will be available in the U.S. as a Class I IHC IVD assay and is CE marked for use in Europe.
    • Completed enrollment of its 1100-patient Phase 3 pivotal trial FAR-131 in 1st-relapsed platinum-sensitive ovarian cancer.
  • January
    • Entered into agreement with Fox Chase Cancer Center to acquire clinical samples essential for the development and validation of companion diagnostic assays.

2011

  • June
    • Initiated Phase 2 clinical study of farletuzumab in first-line non-small cell adenocarcinoma of the lung.
  • May
    • Initiated Phase 2 clinical study of MORAb-004 in metastatic melanoma.
  • April
    • Announced acquisition of tumor-targeting platform from Transmolecular Inc.
    • Received Beacon Award from CancerCare, a patient advocacy group.
    • Received additional funding from the U.S. Department of Defense to support development of therapeutic antibodies to combat biowarfare agents.
  • March
    • Signed agreement with Biocare Medical to develop and commercialize a diagnostic kit for folate receptor alpha-positive malignant tissues.

2010

  • November
    • Initiated a Sponsored Research Agreement with Hokkaido University to evaluate amatuximab in advanced pancreatic cancer.
  • October
    • Received funding from the U.S. Department of Defense to support development of therapeutic antibodies to combat microbial bioweapons.
  • September
    • Morphotek and Human Genome Sciences select a therapeutic monoclonal antibody to advance into development.
  • June
    • Initiated MORAb-022 clinical study in Europe for the treatment of inflammatory disease.
  • May
    • Announced appointment of Dr. Joye Bramble as Vice President of Pilot Plant Operations.
  • April
    • Morphotek and Champions Biotechnology announced an agreement to use Biomerk Tumorgraft platform to evaluate therapeutic antibodies for cancer.
  • March
    • Broke ground for a pilot plant to manufacture biological-based drugs.

2009

  • October
    • Completed a licensing deal with Centocor Ortho for exclusive rights to a therapeutic monoclonal antibody.
  • September
    • Awarded funding from U.S. Department of Defense to develop therapeutic antibodies against biowarfare toxins.
  • August
    • Entered an evaluation and option agreement with Cancer Innovations, Inc. for therapeutic monoclonal antibodies.
  • July
    • Entered a Research Collaboration Agreement with Synageva BioPharma Corporation to develop potential treatments for cancer and infectious disease.
  • June
    • Announced FDA acceptance of Investigational New Drug Application for MORAb-004, a monoclonal antibody for the treatment of cancer.
  • May
    • Entered a Manufacturing Services Agreement with Lonza Group LTD.
  • March
    • Entered a collaboration with Human Genome Sciences to discover, develop and commercialize antibodies for oncology and immunology.
    • Announced FDA Special Protocol Assessment (SPA) for Phase 3 trial evaluating farletuzumab in relapsed ovarian cancer.
    • Initiated MORAb-009 Phase 2 study in 1st-line treatment of mesothelioma
  • January
    • Signed collaboration with University Hospital Heidelberg to develop therapeutic antibodies to treat cancer.

2008

  • December
    • Signed collaboration with University of Pennsylvania to develop antibodies to targets present in hypoxic regions of tumors to treat cancer.
  • November
    • Received funding from U.S. Department of Defense to support development of therapeutic antibodies to treat against biowarfare pathogens.
  • September
    • Signed agreement with Pivotal Biosciences, Inc. to access new antibody technology to improve therapeutic activity.
  • August
    • Opened clinical sites in Europe to expand Phase 2 trial of MORAb-009 in 1st-line pancreatic cancer.
    • Signed collaboration/license agreement with the National Cancer Institute to develop antibodies to a prostate cancer target.
  • July
    • Morphotek Executive, Rodney Dausch, named Small Company CFO of the Year in the Greater Philadelphia Region.
  • June
    • Received funding from U.S. Department of Defense to develop antibodies to treat against infectious disease agents.
  • May
    • Established collaboration with the National Institute of Allergy and Infectious Diseases to develop therapeutic antibodies to treat against infectious pathogens.
  • April
    • Received orphan status from European regulatory authorities for farletuzumab in ovarian cancer and MORAb-009 in pancreatic cancer.
  • March
    • Signed agreement with Human Monoclonal International Inc to license and develop an antibody to treat cancer.
  • January
    • Signed collaboration agreement with the Ludwig Institute to validate disease targets.

2007

  • December
    • Initiated MORAb-009 randomized, controlled Phase 2 study in 1st-line pancreatic cancer.
  • October
    • Received funding from the National Institute of Allergy and Infectious Diseases to develop therapeutic antibodies against biowarfare agents.
  • September
    • Received funding from the U.S. Department of Defense to develop therapeutic antibodies against biowarfare agents.
  • June
    • Morphotek CEO Nicholas Nicolaides named Ernst & Young Entrepreneur Of The Year® 2007 award winner in Greater Philadelphia Region.
  • May
    • Signed Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for therapeutic antibody to treat melanoma.
  • April
    • Acquired by Eisai Corporation.
  • February
    • Obtained exclusive license from Micromet for antibody to treat melanoma and other cancers.
    • President and CEO Nicholas Nicolaides honored as top-20 Scientist by R&D Directions.

2006

  • November
    • Selected as one of the region's top-three fastest-growing companies by Philadelphia 100®.
  • October
    • Raised $40 million to advance its antibody pipeline.
  • June
    • Initiated Phase 2 clinical trial for MORAb-003 in ovarian cancer.
  • February
    • FDA Accepted IND Application for MORAb-009.

2005

  • December
    • Signed exclusive license agreement with the National Cancer Institute (MORAb-009).
  • September
    • Invitrogen Corporation acquired cell line optimization service business.
  • February
    • FDA accepted IND Application for MORAb-003.
    • Nicholas Nicolaides, Morphotek’s President & CEO, was a “40 Under 40” honoree. The award is based on a recipient's commitment to professional excellence and community involvement.
  • January
    • Awarded development grant by NCI.
    • Named “The Company to Watch” by BioExecutive International magazine.

2004

  • December
    • Signed exclusive license agreement with the Ludwig Institute for Cancer Research (MORAb-004).
  • November
    • Named “2004 Technology Company of the Year” by the Greater Philadelphia Chamber of Commerce. This award is based on a company’s achievements, vitality, creativity and impact on their industry.
  • September
    • Signed CRADA with USAMRIID.
  • July
    • Signed cross-license agreement with Protein Design Labs.
  • March
    • Awarded the distinguished “Alumni Award” by the Ben Franklin Technology Partners of Southeastern Pennsylvania.
  • February
    • Raised $26 million in Series C funding.

2003

  • October
    • Signed manufacturing agreement with Baxter Healthcare.

2002

  • September
    • Awarded Pennsylvania Opportunity Grant by PA Governor Mark Schweiker.
  • July
    • Awarded U.S. Army grant.
  • May
    • Expanded operations and relocated to 41,000 sq. ft. facility in Exton, PA.
  • April
    • Signed Research Agreement with the Ludwig Institute for Cancer Research (MORAb-003).
  • March
    • Named “Biotech Company of the Year” by Ben Franklin Technology Partners of Southeastern Pennsylvania, recognizing the exceptional management team, prospects for achieving product commercialization, and significant growth potential.
  • February
    • Signed Research Agreement with the Wistar Institute.
    • Received the “People’s Choice” award at the annual Early Stage East Bio-Life-Tech Conference.

2001

  • August
    • Raised $10 million in Series B funding.
  • February
    • Awarded “Ben Franklin Emerging Fund” by Ben Franklin Technology Partners of Southeastern Pennsylvania.

2000

  • November
    • Established Scientific Advisory Board.
  • July
    • Established Board of Directors.
  • May
    • Founded by Drs. Luigi Grasso, Nicholas Nicolaides and Phillip Sass.